Skip to main content

Skin Cancer Following Solid Organ Transplantation: A Review of Risk Factors and Models of Care

Abstract

The number of solid organ transplants has been increasing annually worldwide. Advances in transplantation surgery and community awareness of organ donation have been key contributors. Combined with increased understanding of immunosuppression, there are a growing number of solid organ transplant recipients in the community as a result of improved long-term outcomes. There remains a high incidence of deaths worldwide post-transplant due to non-melanoma skin cancer (NMSC), which has greater morbidity and mortality in this population than in the general community. Many transplant candidates are not screened prior to organ transplantation and not followed up dermatologically after transplant. After a comprehensive review of the MEDLINE database, we present an update of literature on risk factors for melanoma and non-melanoma skin cancer development in transplant recipients. Medications used by transplant recipients, including immunosuppressants and antibiotics, are discussed along with their respective risks of skin cancer development. We conclude with evidence-based recommendations for models of care, including patient education and dermatological review of transplant recipients.

This is a preview of subscription content, access via your institution.

References

  1. ANZDATA Registry. 39th Report, Chapter 8: Transplantation. Australia and New Zealand Dialysis and Transplant Registry. Adelaide, Australia. 2017. http://www.anzdata.org.au. Accessed 22 Nov 2017.

  2. Madeleine MM, Patel NS, Plasmeijer EI, Engels EA, Bouwes Bavinck JN, Toland AE, et al. Epidemiology of keratinocyte carcinomas after organ transplantation. Br J Dermatol. 2017;177(5):1208–16.

    PubMed  Article  CAS  Google Scholar 

  3. Rüegg CP, Graf N, Mühleisen B, Szucs TD, French LE, Surber C, et al. Squamous cell carcinoma of the skin induces considerable sustained cost of care in organ transplant recipients. J Am Acad Dermatol. 2012;67(6):1242–9.

    PubMed  Article  Google Scholar 

  4. Fransen M, Karahalios A, Sharma N, English DR, Giles GG, Sinclair RD. Non-melanoma skin cancer in Australia. Med J Aust. 2012;197(10):565–8.

    PubMed  Article  Google Scholar 

  5. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Eng J Med. 2003;348(17):1681–91.

    Article  Google Scholar 

  6. Bouwes Bavinck JN, Hardie DR, Green A, Cutmore S, MacNaught A, O’Sullivan B, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation. 1996;61(5):715–21.

    PubMed  Article  CAS  Google Scholar 

  7. Hartevelt MM, Bavinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation. 1990;49(3):506–9.

    PubMed  Article  CAS  Google Scholar 

  8. Ramsay HM, Fryer AA, Hawley CM, Smith AG, Nicol DL, Harden PN. Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol. 2002;147(5):950–6.

    PubMed  Article  CAS  Google Scholar 

  9. Garrett GL, Blanc PD, Boscardin J. Incidence of and risk factors for skin cancer in organ transplant recipients in the United States. JAMA Dermatol. 2017;153(3):296–303.

    PubMed  Article  Google Scholar 

  10. Harwood CA, Mesher D, McGregor JM, Mitchell L, Leedham-Green M, Raftery M, et al. A surveillance model for skin cancer in organ transplant recipients: a 22-year prospective study in an ethnically diverse population. Am J Transplant. 2013;13(1):119–29.

    PubMed  Article  CAS  Google Scholar 

  11. Krynitz B, Edgren G, Lindelof B, Baecklund E, Brattstrom C, Wilczeka H, et al. Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008: A Swedish population-based study. Int J Cancer. 2013;132(6):1429–38.

    PubMed  Article  CAS  Google Scholar 

  12. Lindelöf B, Sigurgeirsson B, Gäbel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol. 2000;143(3):513–9.

    PubMed  Google Scholar 

  13. Mackenzie KA, Wells JE, Lynn KL, Simcock JW, Robinson BA, Roake JA, et al. First and subsequent nonmelanoma skin cancers: incidence and predictors in a population of New Zealand renal transplant recipients. Nephrol Dial Transpl. 2010;25(1):300–6.

    Article  Google Scholar 

  14. Moosa MR. Racial and ethnic variations in incidence and pattern of malignancies after kidney transplantation. Medicine. 2005;84(1):12–22.

    PubMed  Article  Google Scholar 

  15. Ng JC, Cumming S, Leung V, Chong AH. Accrual of non-melanoma skin cancer in renal-transplant recipients: experience of a Victorian tertiary referral institution. Australas J Dermatol. 2014;55(1):43–8.

    PubMed  Article  Google Scholar 

  16. Ong CS, Keogh AM, Kossard S, Macdonald PS, Spratt PM. Skin cancer in Australian heart transplant recipients. J Am Acad Dermatol. 1999;40:27–34.

    PubMed  Article  CAS  Google Scholar 

  17. Engels EA, Pfeiffer RM, Fraumeni JF, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among U.S. solid organ transplant recipients: the transplant cancer match study. JAMA. 2011;306(17):1891–901.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  18. Arnold M, Holterhues C, Hollestein L, Coebergh J, Nijsten T, Pukkala E, et al. Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015. J Eur Acad Dermatol Venereol. 2014;28(9):1170–8.

    PubMed  Article  CAS  Google Scholar 

  19. Guy G, Machlin SR, Ekwueme DU, Yabroff KR. Prevalence and costs of skin cancer treatment in the U.S., 2002–2006 and 2007–2011. Am J Prev Med. 2015;48(2):183–7.

    PubMed  Article  Google Scholar 

  20. Jensen P, Hansen S, Møller B, Leivestad T, Pfeffer P, Geiran O, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40(2):177–86.

    PubMed  Article  CAS  Google Scholar 

  21. Ingvar A, Smedby KE, Lindelöf B, Fernberg P, Bellocco R, Tufveson G, et al. Immunosuppressive treatment after solid organ transplantation and risk of post-transplant cutaneous squamous cell carcinoma. Nephrol Dial Transpl. 2010;25(8):2764–71.

    Article  CAS  Google Scholar 

  22. Harwood CA, Toland AE, Proby CM, Euvrard S, Hofbauer GFL, Tommasino M, et al. The pathogenesis of cutaneous squamous cell carcinoma in organ transplant recipients. Br J Dermatol. 2017;177(5):1217.

    PubMed  Article  CAS  Google Scholar 

  23. O’Donovan P, Perrett CM, Zhang X, Montaner B, Xu Y-Z, Harwood CA, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science. 2005;309(5742):1871–4.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  24. Chockalingam R, Downing C, Tyring SK. Cutaneous squamous cell carcinomas in organ transplant recipients. J Clin Med. 2015;4(6):1229–39.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  25. Bouwes Bavinck JN, Feltkamp MCW, Green AC, Fiocco M, Euvrard S, Harwood CA, et al. Human papillomavirus and post-transplant cutaneous squamous-cell carcinoma: a multicenter, prospective cohort study. Am J Transpl [Internet]. 2017.

  26. Hoshida Y, Tsukuma H, Yasunaga Y, Xu N, Fujita M, Satoh T, et al. Cancer risk after renal transplantation in Japan. Int J Cancer. 1997;71(4):517–20.

    PubMed  Article  CAS  Google Scholar 

  27. Yu S, Gao F, Yu J, Yan S, Wu J, Zhang M, et al. De novo cancers following liver transplantation: a single center experience in China. PLoS One. 2014;9(1):e85651.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  28. Park H, Hwang S, Ahn C, Kim K, Moon D, Ha T, et al. De novo malignancies after liver transplantation: incidence comparison with the Korean cancer registry. Transpl Proc. 2012;44(3):802–5.

    Article  CAS  Google Scholar 

  29. Proby CM, Wisgerhof HC, Casabonne D, Green AC, Harwood CA, Bouwes Bavinck JN. The epidemiology of transplant-associated keratinocyte cancers in different geographical regions. Cancer Treat Res. 2009;146:75–95.

    PubMed  Article  Google Scholar 

  30. Ducroux E, Martin C, Bouwes Bavinck JN, Decullier E, Brocard A, Westhuis-van Elsäcker ME, et al. Risk of aggressive skin cancers after kidney retransplantation in patients with previous posttransplant cutaneous squamous cell carcinomas: a retrospective study of 53 cases. Transplantation. 2017;101(4):e133–41.

    PubMed  Article  CAS  Google Scholar 

  31. Gogia R, Binstock M, Hirose R, Boscardin WJ, Chren M-M, Arron ST. Fitzpatrick skin phototype is an independent predictor of squamous cell carcinoma risk after solid organ transplantation. J Am Acad Dermatol. 2013;68:585–91.

    PubMed  Article  Google Scholar 

  32. Rashtak S, Dierkhising R, Kremers W, Peters S, Cassivi S, Otley C. Incidence and risk factors for skin cancer following lung transplantation. J Am Acad Dermatol. 2015;72(1):92–8.

    PubMed  Article  Google Scholar 

  33. Martinez J, Otley C, Stasko T, Euvrard S, Brown C, Schanbacher C, et al. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol. 2003;139(3):301–6.

    PubMed  Article  Google Scholar 

  34. Garrett GL, Lowenstein SE, Singer JP, He SY, Arron ST. Trends of skin cancer mortality after transplantation in the United States: 1987 to 2013. J Am Acad Dermatol. 2016;75(1):106–12.

    PubMed  Article  Google Scholar 

  35. Lindelöf B, Jarnvik J, Ternesten-Bratel A, Granath F, Hedblad M-A. Mortality and clinicopathological features of cutaneous squamous cell carcinoma in organ transplant recipients: a study of the Swedish cohort. Acta Derm Venereol. 2006;86(3):219–22.

    PubMed  Article  Google Scholar 

  36. Xiol X, Guardiola J, Menendez S, Lama C, Figueras J, Marcoval J, et al. Risk factors for development of de novo neoplasia after liver transplantation. Liver Transpl. 2001;7(11):971–5.

    PubMed  Article  CAS  Google Scholar 

  37. Iannacone MR, Sinnya S, Pandeya N, Isbel N, Campbell S, Fawcett J, et al. Prevalence of skin cancer and related skin tumors in high-risk kidney and liver transplant recipients in Queensland, Australia. J Invest Dermatol. 2016;136(7):1382–6.

    PubMed  Article  CAS  Google Scholar 

  38. Ducroux E, Boillot O, Ocampo MA, Decullier E, Roux A, Dumortier J, et al. Skin cancers after liver transplantation: retrospective single-center study on 371 recipients. Transplantation. 2014;98(3):335–40.

    PubMed  Article  Google Scholar 

  39. Krynitz B, Olsson H, Lundh Rozell B, Lindelof B, Edgren G, Smedby KE. Risk of basal cell carcinoma in Swedish organ transplant recipients: a population-based study. Br J Dermatol. 2016;1:95.

    Article  Google Scholar 

  40. Green A, Olsen C. Increased risk of melanoma in organ transplant recipients: systematic review and meta-analysis of cohort studies. Acta Derm Venereol. 2015;95(8):923–7.

    PubMed  Article  CAS  Google Scholar 

  41. Hollenbeak CS, Todd MM, Billingsley EM, Harper G, Dyer A-M, Lengerich EJ. Increased incidence of melanoma in renal transplantation recipients. Cancer. 2005;104(9):1962–7.

    PubMed  Article  Google Scholar 

  42. Vajdic CM, Chong AH, Kelly PJ, Meagher NS, Van Leeuwen MT, Grulich AE, et al. Survival after cutaneous melanoma in kidney transplant recipients: a population-based matched cohort study. Am J Transpl. 2014;14(6):1368–75.

    Article  CAS  Google Scholar 

  43. Arron S, Canavan T, Yu S. Organ transplant recipients with Merkel cell carcinoma have reduced progression-free, overall, and disease-specific survival independent of stage at presentation. J Am Acad Dermatol. 2014;71(4):684–90.

    PubMed  Article  Google Scholar 

  44. Raeisi D, Payandeh M, Madani SH, Zare ME, Kansestani AN, Hashemian AH. Kaposi’s sarcoma after kidney transplantation: a 21-years experience. Int J Hematol Oncol Stem Cell Res. 2013;7(4):29–33.

    PubMed  PubMed Central  Google Scholar 

  45. Kang W, Sampaio MS, Huang E, Bunnapradist S. Association of pretransplant skin cancer with posttransplant malignancy, graft failure and death in kidney transplant recipients. Transplantation. 2017;101(6):1303–9.

    PubMed  Article  Google Scholar 

  46. Krynitz B, Rozell B, Lyth J, Smedby K, Lindelöf B. Cutaneous malignant melanoma in the Swedish organ transplantation cohort: a study of clinicopathological characteristics and mortality. J Am Acad Dermatol. 2015;73(1):106–13.e2.

  47. Teulings H-E, Limpens J, Jansen S, Zwinderman A, Reitsma J, Spuls P, et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015;33(7):773–81.

    PubMed  Article  CAS  Google Scholar 

  48. Kanitakis J, Baldassini S, Lora V, Euvrard S. BRAF mutations in melanocytic tumors (nevi and melanomas) from organ transplant recipients. Eur J Dermatol. 2010;20(2):167–71.

    PubMed  CAS  Google Scholar 

  49. Lee J, Choi J, Kim Y. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol. 2011;164(4):776–84.

    PubMed  Article  CAS  Google Scholar 

  50. Brocard A, Knol A, Bossard C, Denis M, Quéreux G, Saint-Jean M, et al. Clinical, genetic and innate immunity characteristics of melanoma in organ transplant recipients. Acta Derm Venereol. 2017;97(4):483–8.

    PubMed  Article  CAS  Google Scholar 

  51. Clarke C, Robbins H, Tatalovich Z, Lynch C, Pawlish K, Finch J, et al. Risk of merkel cell carcinoma after solid organ transplantation. J Natl Cancer Inst. 2015;107(2):dju382.

  52. Sharp C, Norja P, Anthony I, Bell J, Simmonds P. Reactivation and mutation of newly discovered WU, KI, and Merkel cell carcinoma polyomaviruses in immunosuppressed individuals. J Infect Dis. 2009;199(3):398–404.

    PubMed  Article  Google Scholar 

  53. Antman K, Chang Y. Kaposi’s sarcoma. N Eng J Med. 2000;342(14):1027–38.

    Article  CAS  Google Scholar 

  54. Harwood CA, McGregor JM, Swale VJ, Proby CM, Leigh IM, Newton R, et al. High frequency and diversity of cutaneous appendageal tumors in organ transplant recipients. J Am Acad Dermatol. 2003;48(3):401–8.

    PubMed  Article  Google Scholar 

  55. Wheless L, Jacks S, Potter KAM, Leach BC, Cook J. Skin cancer in organ transplant recipients: more than the immune system. J Am Acad Dermatol. 2014;71(2):359–65.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  56. Kaufmann R, Oberholzer P, Cazzaniga S, Hunger R. Epithelial skin cancers after kidney transplantation: a retrospective single-centre study of 376 recipients. Eur J Dermatol. 2016;26(3):265–70.

    PubMed  CAS  Google Scholar 

  57. Yarosh DB, Pena AV, Nay SL, Canning MT, Brown DA. Calcineurin inhibitors decrease dna repair and apoptosis in human keratinocytes following ultraviolet b irradiation. J Invest Dermatol. 2005;125:1020–5.

    PubMed  Article  CAS  Google Scholar 

  58. Dziunycz P, Lefort K, Wu X, Freiberger S, Neu J, Djerbi N, et al. The oncogene ATF3 is potentiated by cyclosporine A and ultraviolet light A. J Invest Dermatol. 2014;134(7):1998–2004.

    PubMed  Article  CAS  Google Scholar 

  59. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999;397(6719):530–4.

    PubMed  Article  CAS  Google Scholar 

  60. Jensen P, Hansen S, Møller B, Leivestad T, Pfeffer P, Fauchald P. Are renal transplant recipients on CsA-based immunosuppressive regimens more likely to develop skin cancer than those on azathioprine and prednisolone? Transpl Proc. 1999;31(1–2):1120.

  61. Crespo-Leiro M, Alonso-Pulpón L, Vázquez de Prada J, Almenar L, Arizón J, Brossa V, et al. Malignancy after heart transplantation: incidence, prognosis and risk factors. Am J Transpl. 2008;8(5):1031–9.

    Article  CAS  Google Scholar 

  62. Molina B, Leiro M, Pulpón L, Mirabet S, Yañez J, Bonet L, et al. Incidence and risk factors for nonmelanoma skin cancer after heart transplantation. Transpl Proc. 2010;42(8):3001–5.

    Article  CAS  Google Scholar 

  63. Ming M, Zhao B, Qiang L, He Y-Y. Effect of Immunosuppressants tacrolimus and mycophenolate mofetil on the keratinocyte UVB response. Photochem Photobiol. 2015;1:242.

    Article  CAS  Google Scholar 

  64. Wu X, Nguyen B, Dziunycz P, Chang S, Brooks Y, Lefort K, et al. Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature. 2010;465(7296):368–72.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  65. Kasiske B, Snyder J, Gilbertson D, Wang C. Cancer after kidney transplantation in the United States. Am J Transpl. 2004;4(6):905–13.

    Article  Google Scholar 

  66. Navarro M, López-Andréu M, Rodríguez-Benot A, Agüera M, Del Castillo D, Aljama P. Cancer incidence and survival in kidney transplant patients. Transpl Proc. 2008;40(9):2936–40.

    Article  CAS  Google Scholar 

  67. Krásová M, Sečníková Z, Göpfertová D, Hercogová J, Viklický O, Jůzlová K, et al. Immunosuppressive therapy in the posttransplant period and skin cancer. Dermatol Ther. 2016;29(6):433–6.

    PubMed  Article  Google Scholar 

  68. Watorek E, Boratynska M, Smolska D, Patrzalek D, Klinger M. Malignancy after renal transplantation in the new era of immunosuppression. Ann Transpl. 2011;16(2):14–8.

    Article  CAS  Google Scholar 

  69. Wimmer C, Angele M, Schwarz B, Pratschke S, Rentsch M, Khandoga A, et al. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients. Transpl Int. 2013;26(10):999–1006.

    PubMed  Article  CAS  Google Scholar 

  70. Knoll GA, Kokolo MB, Mallick R, Beck A, Buenaventura CD, Ducharme R, et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ (Clinical Research Ed). 2014;349:g6679–g.

  71. Jung J-W, Overgaard NH, Burke MT, Isbel N, Frazer IH, Simpson F, et al. Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients? Int J Cancer. 2016;138(2):281–92.

    PubMed  Article  CAS  Google Scholar 

  72. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation. 2005;80(7):883–9.

    PubMed  Article  CAS  Google Scholar 

  73. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant. 2004;18(4):446–9.

    PubMed  Article  Google Scholar 

  74. Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Eng J Med. 2012;367(4):329–39.

    Article  CAS  Google Scholar 

  75. Hoogendijk-van den Akker JM, Harden PN, Hoitsma AJ, Proby CM, Wolterbeek R, Bouwes Bavinck JN, et al. Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. J Clin Oncol. 2013;31(10):1317–23.

    PubMed  Article  CAS  Google Scholar 

  76. Lim WH, Eris J, Kanellis J, Pussell B, Wiid Z, Witcombe D, et al. A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients. Am J Transpl. 2014;14(9):2106–19.

    Article  CAS  Google Scholar 

  77. de Fijter JW. Cancer and mTOR inhibitors in transplant recipients. Transplantation. 2017;101(1):45–55.

    PubMed  Google Scholar 

  78. Feldmeyer L, Hofbauer GFL, Böni T, French LE, Hafner J. Mammalian target of rapamycin (mTOR) inhibitors slow skin carcinogenesis, but impair wound healing. Br J Dermatol. 2012;166(2):422–4.

    PubMed  Article  CAS  Google Scholar 

  79. Meier F, Guenova E, Clasen S, Eigentler T, Forschner A, Leiter U, et al. Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients. J Am Acad Dermatol. 2009;60(5):863–8.

    PubMed  Article  Google Scholar 

  80. Guven M, Brem R, Macpherson P, Peacock M, Karran P. Oxidative damage to RPA limits the nucleotide excision repair capacity of human cells. J Invest Dermatol. 2015;135(11):2834–41.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  81. Jiyad Z, Olsen CM, Burke MT, Isbel NM, Green AC. Azathioprine and risk of skin cancer in organ transplant recipients: systematic review and meta-analysis. Am J Transpl. 2016;16(12):3490–503.

    Article  CAS  Google Scholar 

  82. Coghill AE, Johnson LG, Berg D, Resler AJ, Leca N, Madele MM. Immunosuppressive medications and squamous cell skin carcinoma: nested case-control study within the skin cancer after organ transplant (SCOT) cohort. Am J Transpl. 2016;16(2):565–73.

    Article  CAS  Google Scholar 

  83. de Gruijl FR, Koehl GE, Voskamp P, Strik A, Rebel HG, Gaumann A, et al. Early and late effects of the immunosuppressants rapamycin and mycophenolate mofetil on UV carcinogenesis. Int J Cancer. 2010;127(4):796–804.

    PubMed  Google Scholar 

  84. Aguiar D, Martínez-Urbistondo D, D’Avola D, Iñarrairaegui M, Pardo F, Rotellar F, et al. Conversion from calcineurin inhibitor-based immunosuppression to mycophenolate mofetil in monotherapy reduces risk of de novo malignancies after liver transplantation. Ann Transpl. 2017;22:141–7.

    Article  CAS  Google Scholar 

  85. Piponniau L, Kittleson M, Patel J, Rafiei M, Osborne A, Dhiantravan V, et al. Mycophenolate not azathioprine is associated with increased risk for skin cancer after heart transplant. J Heart Lung Transpl. 2013;32(4):S199.

    Article  Google Scholar 

  86. Wang YJ, Chi NH, Chou NK, Huang SC, Wang CH, Wu IH, et al. Malignancy after heart transplantation under everolimus versus mycophenolate mofetil immunosuppression. Transpl Proc. 2016;48(3):969–73.

    Article  CAS  Google Scholar 

  87. Dharnidharka V, Schnitzler M, Chen J, Brennan D, Axelrod D, Segev D, et al. Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study. Transpl Int. 2016;29(11):1226–36.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  88. Gerber SR, Seifert B, Inci I, Serra AL, Kohler M, Benden C, et al. Exposure to moxifloxacin and cytomegalovirus replication is associated with skin squamous cell carcinoma development in lung transplant recipients. J Eur Acad Dermatol Venereol. 2015;12:2451.

    Article  CAS  Google Scholar 

  89. Browne BJ, Young J-A, Dunn TB, Matas AJ. The impact of cytomegalovirus infection ≥ 1 year after primary renal transplantation. Clin Transplant. 2010;24(4):572–7.

    PubMed  PubMed Central  Article  Google Scholar 

  90. Hasanzamani B, Hami M, Zolfaghari V, Torkamani M, Sabagh MG, Simab SA. The effect of cytomegalovirus infection on acute rejection in kidney transplanted patients. J Renal Inj Prev. 2016;5(2):85–8.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  91. Epstein ME, Amodio-Groton M, Sadick NS. Antimicrobial agents for the dermatologist. II. Macrolides, fluoroquinolones, rifamycins, tetracyclines, trimethoprim-sulfamethoxazole, and clindamycin. J Am Acad Dermatol. 1997;37(3 Pt 1):365–81.

  92. Neoh CF, Snell GI, Levvey B, Kotsimbos T, Morrissey O, Slavin MA, et al. Lung transplant recipients receiving voriconazole and skin squamous cell carcinoma risk in Australia. Med J Aust. 2014;201(9):543–4.

    PubMed  Article  Google Scholar 

  93. Mansh M, Binstock M, Williams K, Hafeez F, Kim J, Glidden D, et al. Voriconazole exposure and risk of cutaneous squamous cell carcinoma, aspergillus colonization, invasive aspergillosis and death in lung transplant recipients. Am J Transpl. 2016;16(1):262–70.

    Article  CAS  Google Scholar 

  94. Williams K, Mansh M, Chin-Hong P, Singer J, Arron ST. Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients. Clin Infect Dis. 2014;58(7):997–1002.

    PubMed  Article  Google Scholar 

  95. Kolaitis NA, Duffy E, Zhang A, Lo M, Barba DT, Chen M, et al. Voriconazole increases the risk for cutaneous squamous cell carcinoma after lung transplantation. Transpl Int. 2017;30(1):41–8.

    PubMed  Article  CAS  Google Scholar 

  96. Jacobsen AA, Papo YB, Sarro R, Weisse K, Strasswimmer J. Posaconazole substitution for voriconazole-associated phototoxic effects. JAMA Dermatol. 2016;152(7):839–41.

    PubMed  Article  Google Scholar 

  97. Otley CC. Organization of a specialty clinic to optimize the care of organ transplant recipients at risk for skin cancer. Dermatol Surg. 2000;26(7):709–12.

    PubMed  Article  CAS  Google Scholar 

  98. Patel P, Bibee K, Lim G, Malik S, Wu C, Pugliano-Mauro M. Evaluating retention of skin cancer education in kidney transplant recipients reveals a window of opportunity for re-education. Transpl Proc. 2017;49(6):1318–24.

    Article  CAS  Google Scholar 

  99. Lloyd A, Klintmalm G, Qin H, Menter A. Skin cancer evaluation in transplant patients: a physician opinion survey with recommendations. Clin Transpl. 2015;29(2):110–7.

    Article  Google Scholar 

  100. Christenson L, Geusau A, Ferrandiz C, Brown C, Ulrich C, Stockfleth E, et al. Specialty clinics for the dermatologic care of solid-organ transplant recipients. Dermatol Surg. 2004;30(4):598–603.

    PubMed  Article  Google Scholar 

  101. Clowers-Webb HE, Christenson LJ, Phillips PK, Roenigk RK, Nguyen TH, Weaver AL, et al. Educational outcomes regarding skin cancer in organ transplant recipients: randomized intervention of intensive vs standard education. Arch Dermatol. 2006;142(6):712–8.

    PubMed  Article  Google Scholar 

  102. Leung VKY, Dobbinson SJ, Goodman DJ, Kanellis J, Chong AH. Skin cancer history, sun-related attitudes, behaviour and sunburn among renal transplant recipients versus general population. Australas J Dermatol. 2017.

  103. Ulrich C, Jürgensen J, Degen A, Hackethal M, Ulrich M, Patel M, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol. 2009;161(S3):78–84.

    PubMed  Article  Google Scholar 

  104. Reichrath J. Solar ultraviolet radiation, vitamin D and skin cancer surveillance in organ transplant recipients (OTRs): an update. Adv Exp Med Biol. 2014;810:253–71.

    PubMed  Google Scholar 

  105. Ismail F, Mitchell L, Casabonne D, Gulati A, Newton R, Proby CM, et al. Specialist dermatology clinics for organ transplant recipients significantly improve compliance with photoprotection and levels of skin cancer awareness. Br J Dermatol. 2006;155(5):916–25.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  106. O’Reilly Zwald F, Brown M. Continuing medical education: skin cancer in solid organ transplant recipients: Advances in therapy and management. Part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol. 2011;65(2):263–79.

    PubMed  Article  Google Scholar 

  107. Bavinck JN, Tieben LM, Van der Woude FJ, Tegzess AM, Hermans J, ter Schegget J, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol. 1995;13(8):1933–8.

    PubMed  Article  CAS  Google Scholar 

  108. George R, Weightman W, Russ GR, Bannister KM, Mathew TH. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol. 2002;43(4):269–73.

    PubMed  Article  Google Scholar 

  109. Harwood CA, Leedham-Green M, Leigh IM, Proby CM. Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study. Arch Dermatol. 2005;141(4):456–64.

    PubMed  Article  CAS  Google Scholar 

  110. De Graaf YGL, Euvrard S, Bouwes Bavinck JN. Systemic and topical retinoids in the management of skin cancer in organ transplant recipients. Dermatol Surg. 2004;30(4 Pt 2):656–61.

    PubMed  Google Scholar 

  111. Chen AC, Martin AJ, Choy B, Fernandez-Penas P, McKenzie CA, Vardy JL, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Eng J Med. 2015;373(17):1618–26.

    Article  CAS  Google Scholar 

  112. Chen AC, Martin AJ, Dalziell RA, McKenzie CA, Lowe PM, Eris JM, et al. A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. Br J Dermatol. 2016;175(5):1073–5.

    PubMed  Article  CAS  Google Scholar 

  113. Drago F, Ciccarese G, Cogorno L, Calvi C, Marsano L, Parodi A. Prevention of non-melanoma skin cancers with nicotinamide in transplant recipients: a case–control study. Eur J Dermatol. 2017;27(4):382–5.

    PubMed  Google Scholar 

  114. Otley C, Berg D, Ulrich C, Stasko T, Murphy G, Salasche S, et al. Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey. Br J Dermatol. 2006;154(3):395–400.

    PubMed  Article  CAS  Google Scholar 

  115. Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 1998;351(9103):623–8.

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Matthew D. Howard.

Ethics declarations

Funding

No external funding was used in the preparation of this manuscript.

Conflicts of interest

Matthew Howard, John Su, and Alvin Chong declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Howard, M.D., Su, J.C. & Chong, A.H. Skin Cancer Following Solid Organ Transplantation: A Review of Risk Factors and Models of Care. Am J Clin Dermatol 19, 585–597 (2018). https://doi.org/10.1007/s40257-018-0355-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-018-0355-8